Angiopoietin-2 is implicated in the regulation of tumor angiogenesis

被引:115
作者
Yu, Q
Stamenkovic, I
机构
[1] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA
[2] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
关键词
D O I
10.1016/S0002-9440(10)63998-3
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We addressed the effect of angiopoietin expression on tumor growth and metastasis. Overexpression of angiopoietin-2 (Ang-2) in Lewis lung carcinoma and TA3 mammary carcinoma cells inhibited their ability to form metastatic tumors and prolonged the survival of mice injected with the corresponding transfectants. In contrast, angiopoietin-1 (Ang-l) overexpression had no detectable effect on the ability of either tumor type to disseminate. Tumors derived from Ang-2-overexpressing cells displayed aberrant angiogenic vessels that took the form of vascular cords or aggregated vascular endothelial cells with few associated smooth muscle cells. These vascular cords or aggregates were accompanied by endothelial and tumor cell apoptosis, suggesting that an imbalance in Ang-2 expression with respect to Ang-1 and vascular endothelial growth factor may disrupt angiogenesis and tumor survival in vivo. Our observations suggest that Ang-2 may play an important role in regulating tumor angiogenesis.
引用
收藏
页码:563 / 570
页数:8
相关论文
共 32 条
[1]   Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning [J].
Davis, S ;
Aldrich, TH ;
Jones, PF ;
Acheson, A ;
Compton, DL ;
Jain, V ;
Ryan, TE ;
Bruno, J ;
Radziejewski, C ;
Maisonpierre, PC ;
Yancopoulos, GD .
CELL, 1996, 87 (07) :1161-1169
[2]  
DUMONT DJ, 1992, ONCOGENE, V7, P1471
[3]   DOMINANT-NEGATIVE AND TARGETED NULL MUTATIONS IN THE ENDOTHELIAL RECEPTOR TYROSINE KINASE, TEK, REVEAL A CRITICAL ROLE IN VASCULOGENESIS OF THE EMBRYO [J].
DUMONT, DJ ;
GRADWOHL, G ;
FONG, GH ;
PURI, MC ;
GERTSENSTEIN, M ;
AUERBACH, A ;
BREITMAN, ML .
GENES & DEVELOPMENT, 1994, 8 (16) :1897-1909
[4]   Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].
Ferrara, N ;
CarverMoore, K ;
Chen, H ;
Dowd, M ;
Lu, L ;
OShea, KS ;
PowellBraxton, L ;
Hillan, KJ ;
Moore, MW .
NATURE, 1996, 380 (6573) :439-442
[5]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[6]   ROLE OF THE FLT-1 RECEPTOR TYROSINE KINASE IN REGULATING THE ASSEMBLY OF VASCULAR ENDOTHELIUM [J].
FONG, GH ;
ROSSANT, J ;
GERTSENSTEIN, M ;
BREITMAN, ML .
NATURE, 1995, 376 (6535) :66-70
[7]   Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development [J].
Gale, NW ;
Yancopoulos, GD .
GENES & DEVELOPMENT, 1999, 13 (09) :1055-1066
[8]   Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J].
Hanahan, D ;
Folkman, J .
CELL, 1996, 86 (03) :353-364
[9]   Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF [J].
Holash, J ;
Maisonpierre, PC ;
Compton, D ;
Boland, P ;
Alexander, CR ;
Zagzag, D ;
Yancopoulos, GD ;
Wiegand, SJ .
SCIENCE, 1999, 284 (5422) :1994-1998
[10]   HOW DOES EXTRACELLULAR-MATRIX CONTROL CAPILLARY MORPHOGENESIS [J].
INGBER, DE ;
FOLKMAN, J .
CELL, 1989, 58 (05) :803-805